Nutanix's stock rises on earnings, revenue beats
Nutanix Inc.'s (NTNX) stock jumped more than 6% in extended trading Wednesday after the cloud-software company reported quarterly results that eclipsed analyst revenue and earnings estimates. Nutanix reported a fiscal-first-quarter net loss of $15.8 million, or 7 cents a share, compared with a net loss of $99.5 million, or 44 cents a share, in the same quarter a year ago. Adjusted earnings were 29 cents a share. Revenue was $511 million, compared with $433.6 million in the same quarter a year ago. Analysts surveyed by FactSet had expected on average net earnings of 18 cents a share on revenue of $501 million. "AI is a long-term event at all levels for our enterprise customers, but many of them are in an experimental phase," Nutanix Chief Executive Rajiv Ramaswami said in an interview. "What we do is very central for any company going through a digital transformation and cost conscious." Nutanix's stock has propelled 59.5% this year, while the broader S&P 500 index has increased 18.5%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-29-23 1825ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks